Nicholas A Saccomano sold $259 of OKUR
President and CEO at OnKure Therapeutics, Inc.. 87 shares at an average of $2.97, traded Sep 21, 2026, filed Sep 23, 2026.
Score components
- +25RoleCEO
- 0Trade size$259 at market
- 0Share of holdings soldSold 0.8% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001609284-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | SOpen-market sale Class A Common Stock | -87 | $2.97 | $259 | 11,160 | 20 d ago |
Related signals
Other insiders at OnKure Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $898 302 shares | -2% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $1,251 301 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $357 86 shares | -1% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $896 302 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $258 87 shares | -1% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $795 303 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $231 88 shares | -2% | |
| 30Weak | OnKure Therapeutics, Inc. | Jason A. Leverone Chief Financial Officer | $722 303 shares | -2% | |
| 33Weak | OnKure Therapeutics, Inc. | Nicholas A Saccomano President and CEO | $210 88 shares | -2% | |
| 50Moderate | OKURbuy OnKure Therapeutics, Inc. | Acorn Bioventures, L.p. owner | $2.6M 1,400,000 shares | +97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.